Bilaterial-breast-reconstruction

Approximately 60% of breast cancer patients who opted for breast reconstruction are expected to undergo bilateral breast reconstruction surgery in 2014.

The U.S. soft tissue reinforcement and regeneration market is expected to exceed $3.7 billion by 2021. This market is segmented into breast reconstruction, hernia repair, dural repair, vaginal slings, skin repair, sports medicine and tendon reinforcement, and dental soft tissue regeneration.

Approximately 300,000 new cases of breast cancer were diagnosed in the U.S. in 2014. Additionally, “the incidence of invasive breast cancer in younger women under the age of 40 has been increasing; this population is most likely to opt for a reconstructive procedure following mastectomy”, says Dr. Kamran Zamanian, CEO of iData. Over 130,000 mastectomies are estimated to be performed in the U.S. in 2014, and of these, over 70% of patients elected the breast reconstruction surgery. This percentage was significantly higher in the U.S. compared with other countries in the world.

Breast reconstruction is one of the fastest growing segments driving the overall market. This can be attributed to the increased number of breast cancer patients who have decided to undergo breast reconstruction surgery, in particular, bilateral breast reconstruction surgery. The main trend that is driving the high rate of bilateral breast reconstruction in the U.S. is the increased tendency for women to opt for a contralateral prophylactic mastectomy (CPM), a risk reducing mastectomy for patients diagnosed with breast cancer.

Competitive Market Overview

LifeCell’s domination in the U.S. breast reconstruction market is due to its AlloDerm®product. AlloDerm® has  amassed favorable clinical evidence supporting its use such as decreased side effects, superior stretch ability, faster recovery and lower chance of graft rejection. Since its introduction to the market, AlloDerm® has become the gold standard for breast reconstruction procedures.

Ethicon is represented with its pre-hydrated acellular dermal matrix (ADM) product, FlexHD®, which is available through a strategic alliance between Ethicon and the Musculoskeletal Transplant Foundation (MTF). This product is supported with ongoing clinical trials that have shown favourable results thus far.

Other key and notable players include C. R. Bard, Covidien and TEI Biosciences.

For more information

The “U.S. soft tissue reinforcement and regeneration market – 2015” report provides a comprehensive analysis including procedure numbers, units sold, market value, forecasts, as well as a detailed competitive market shares and analysis of major players’ success strategies in each market and segment.

Receive a free synopsis of this U.S. soft tissue reinforcement and regeneration market report by registering or emailing [email protected]